Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pediatrix Medical (MD)

Pediatrix Q2 net income rises to $39.8 million; 2026 EBITDA outlook reaffirmed

Positive Impact 3 of 5 earnings Written later

Pediatrix Medical Group reported second-quarter 2026 revenue of $487.8 million, up 4.0% from a year earlier, and net income of $39.8 million, or $0.49 per diluted share, compared with $0.46 in the prior-year quarter. The company reaffirmed its full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million, though same-unit patient volume fell 2.1%.

Key points

  • Q2 2026 net revenue of $487.8 million, up 4.0% from $468.8 million a year earlier
  • Net income of $39.8 million, or $0.49 per diluted share, vs. $0.46 in Q2 2025
  • Adjusted EPS of $0.63 vs. $0.53; Adjusted EBITDA of $76.4 million vs. $73.2 million
  • Full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million reaffirmed; same-unit volume down 2.1%

The filing

CompanyPediatrix Medical (MD)
Form8-K, current report
Filed with the SECAug 4, 2026, 6:50 AM ET
Accession number0001193125-26-331488

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.